Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.48 |
| ▸ | CA1 | P00915 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | CA9 | Q16790 | 7/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 5/20 | 0.39 |
| ▸ | CA4 | P22748 | 4/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | CTSA | P10619 | 3/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002182 | 0.91 | PTGS2 (0.41) | CA12CA1CA2CA9ADAMTS4 | |
| SCHEMBL6002042 | 0.89 | CA1 (0.44) | CA12CA1CA2CA9CA4 | |
| SCHEMBL6000520 | 0.84 | CA1 (0.52) | CA12CA1CA2CA9ADAMTS4 | |
| SCHEMBL5734311 | 0.82 | CA1 (0.49) | CA12CA1CA2CA9DRD1 | |
| SCHEMBL5732083 | 0.82 | KMT2A (0.41) | CA12CA1CA2CA9DRD1 | |
| SCHEMBL6002022 | 0.80 | CA1 (0.46) | CA12CA1CA2CA9DRD1 | |
| SCHEMBL5733045 | 0.80 | DRD1 (0.40) | CA12CA1CA2CA9DRD1 | |
| SCHEMBL6002011 | 0.80 | PTGS2 (0.40) | DRD1PTGS2CTSAPTGS1 | |
| SCHEMBL5823422 | 0.77 | CA2 (0.48) | CA12CA1CA2CA9DRD1 | |
| SCHEMBL8552551 | 0.74 | CA2 (0.44) | CA12CA1CA2CA9DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | claimed |
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229347-A1 | Treatment of eczemas | ZAP70, SYK, LCK | CA12 2686/4885CA1 3406/4885CA2 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.